Patents by Inventor Yongyong Wu

Yongyong Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052576
    Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.
    Type: Application
    Filed: March 18, 2019
    Publication date: February 25, 2021
    Inventors: Yongyong WU, Jiaqiang CAI, Guangchao ZHANG, Shuangshuang DUAN, Chaolei WANG, Lichun WANG, Jingyi WANG
  • Publication number: 20200361911
    Abstract: Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 19, 2020
    Inventors: Shuai SONG, Qiang TIAN, Yongyong WU, Mingliang ZHAO, Chaolei WANG, Jiaqiang CAI, Lichun WANG, Jingyi WANG
  • Publication number: 20200339558
    Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
    Type: Application
    Filed: December 7, 2018
    Publication date: October 29, 2020
    Applicant: SICHUAN KELUN-BiOTECH BIGPHARMACEUTICAL CO., LTD.
    Inventors: JINMING LIU, JIAQIANG CAI, YONGYONG WU, WEI YIN, LUCHUN WANG, JINGYI WANG
  • Publication number: 20200109166
    Abstract: The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with ?-opioid receptor. The polyamide compound of the invention has excellent ?-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 9, 2020
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang CAI, Qiang TIAN, Mingliang ZHAO, Hong ZENG, Hongmei SONG, Nan YU, Hua DENG, Wei ZHONG, Long YANG, Lei WU, Haitao HUANG, Yongyong WU, Donghai SU, Xin ZHOU, Yuting TAN, Lichun WANG, Jingyi WANG
  • Publication number: 20120302534
    Abstract: The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X, and Y are as described herein. Compounds of the present invention are useful for the treatment of HIV-1.
    Type: Application
    Filed: February 9, 2011
    Publication date: November 29, 2012
    Inventors: Daxin Gao, Nianhe Han, Zhimin Jin, Fangxian Ning, Jun Tang, Yongyong Wu, Heping Yang